Intarcia Therapeutics

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies that optimize and enhance the efficacy, continuous delivery, and tolerability of drug treatments. Moreover, administering medication only once or twice a year essentially ensures patient compliance, which is typically very poor in most chronic conditions. Intarcia's expertise and competitive edge in drug development are reflected in its ability to stabilize proteins and peptides at temperatures above body temperature and deliver them consistently and uniformly through its proprietary technology platform. Intarcia is pursuing a two-phase development program for Type 3 diabetes and is also conducting additional weight management programs to address obesity.